Open Access Research Protocol

Study the Visual Pathway in Patients Taking Hydroxychloroquine

Mandijo Nukatij*

Department of Ophthalmology and optic study, University in Wuhan, China

Corresponding Author

Received Date: June 19, 2019;  Published Date: June 27, 2019


Hydroxychloroquine is considered a disease-modifying anti-rheumatic drug (DMARD). It can decrease the pain and swelling of arthritis. It may prevent joint damage and reduce the risk of long-term disability. This drug is having certain side effect on retina in visual system. The purpose of this study is to check the visual pathway of this patients using visual evoked potential (VEP). Twenty-eight patients suffering from rheumatic arthritis were selected in this study. They were under 200 mg/day of HCQ treatment for at least 19 months. VEP test was examined in all patients. The results obtained was compared with the control group. The mean latency and amplitude of VEP in patient group were 88/8.26 msec and 9.7/3.15 μv and 97/9.31 msec and 8.4/7.18 μv in control group respectively. There were not statistical differences between mean latency and amplitude of VEP, P100 peak as far as case and control groups are concerned. It can be concluded that Hydroxychloroquine does not affect visual pathway seriously.

Keywords:Hydroxychloroquine; Visual pathway; Visual evoked potential; Rheumatoid arthritis

Signup for Newsletter
Scroll to Top